



Amal Therapeutics receives CTI grant to evaluate immunotherapy combination treatments

Geneva, Switzerland, March 8, 2016 – Amal Therapeutics, a Swiss biotech start-up company developing and progressing therapeutic vaccines in oncology, today announced that it received a grant from the Swiss Commission for Technology & Innovation (CTI) to validate immunotherapies combination treatments.

This project, established in collaboration with the laboratory of Tumour Immunology of Dr. Paul Walker from the University of Geneva, has for objective to evaluate the possible combination and synergy of Amal's vaccine with various immuno-modulators.

Dr. Madiha Derouazi, CEO at Amal Therapeutics commented: *“The CTI is an essential partner for Amal Therapeutics. This grant will allow Amal Therapeutics to extend its R&D activities in the field of combinations therapies which are predicted to completely reshape the landscape of cancer treatment in a close future.”*

About the Swiss Commission for Technology and Innovation

The CTI is the federal innovation promotion agency responsible for encouraging science-based innovation in Switzerland by providing financing, professional advice and networks. For further information about the CTI, please visit: <https://www.kti.admin.ch/kti/en/home.html>

About Amal Therapeutics

Amal Therapeutics SA is a privately held Swiss biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses KISIMA, its proprietary vaccine technology platform to develop and progress therapeutic vaccines in oncology. www.amaltherapeutics.com, contact@amaltherapeutics.com